Back to home

EASYHALER IN ASTHMA GUIDELINES

Product info | 01/12/2020
EASYHALER IN ASTHMA GUIDELINES

ONE DEVICE AT EVERY STEP OF THE BTS / SIGN
ASTHMA GUIDELINES1

When considering the environmental impact of inhaler devices, BTS / SIGN advises that where it is clinically appropriate to do so:

DPIs should be prioritised where patients are using multiple device classes and displaying poor inhaler technique

For new prescriptions, DPIs are prioritised

Future and additional inhalers would ideally also be DPIs

 

WITH THE EASYHALER® RANGE, YOU CAN:

  • Prescribe a low dose ICS for new patients (aged 6 years and over) with Easyhaler Budesonide (budesonide)2

  • Prescribe a range of drug therapies within the Easyhaler® range and have the flexibility to move patients across the BTS / SIGN guidelines to find and maintain the lowest controlling therapy.1

  • Provide initial add on therapy with Fobumix Easyhaler (budesonide / formoterol fumarate dihydrate) (adults only) and Fusacomb Easyhaler (salmeterol xinafoate / fluticasone dihydrate) (12 years and above)3,4

 

bts-green.png

bts-orange.png

Download your "Easyhaler and The Guidelines"
to discover where Easyhaler sits in
the BTS / SIGN guidelines.

 

DOWNLOAD

 

 

REFERENCES:

  1. BTS/SIGN. Position Statement The Environment and Lung Health March 2020. https://www.brit-thoracic.org.uk/document-library/governance-and-policy-documents/positionstatements/environment-and-lung-health-position-statement-2020/

 

BTS / SIGN = British Thoracic Society / Scottish Intercollegiate Guidelines Network
ICS = Inhaled Corticosteroids, SmPC = Summary of Product Characteristics
DPI = Dry powder inhalers

 

March 2021 / RESP-330bbf(1)

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Orion Pharma (UK) Ltd on
01635 520300.

ORIONPHARMA.CO.UK

 

Full prescribing information available here

 

MAY 2021 / RESP-330b(3)

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300.

Orion Pharma (UK) Ltd, Abbey Gardens, 4 Abbey Street, Reading, RG1 3BA, UK | Tel: +44 1635 520 300 | February 2021 / RESP-330(1)
Policies Contact us Orion Corporation 2021